US 12,319,694 B2
Heterocyclic nitrogen-containing purine derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection
Gabriel Gonzales, Vrbatky (CZ); Vaclav Mik, Grygov (CZ); Noemi Bucharova, Vysokov (CZ); Jiri Gruz, Bohunovice (CZ); Petr Kanovsky, Vranov (CZ); Miroslav Strnad, Olomouc (CZ); and Marek Zatloukal, Sumperk (CZ)
Assigned to UNIVERZITA PALACKEHO, Olomouc (CZ); and FAKULTNI NEMOCNICE OLOMOUC, Olomouc (CZ)
Appl. No. 17/426,804
Filed by UNIVERZITA PALACKEHO, Olomouc (CZ); and FAKULTNI NEMOCNICE OLOMOUC, Olomouc (CZ)
PCT Filed Jan. 27, 2020, PCT No. PCT/CZ2020/050004
§ 371(c)(1), (2) Date Jul. 29, 2021,
PCT Pub. No. WO2020/164648, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. CZ2019-82 (CZ), filed on Feb. 12, 2019.
Prior Publication US 2022/0127269 A1, Apr. 28, 2022
Int. Cl. C07D 473/16 (2006.01); A61K 31/52 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01)
CPC C07D 473/16 (2013.01) [A61K 31/52 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01)] 9 Claims
 
1. Heterocyclic nitrogen-containing purine derivative of the general formula I,

OG Complex Work Unit Chemistry
wherein
R are independently selected from the group consisting of H, Cl, Br, methyl, OH, and methoxy, and n=1 or 2;
R1 is independently on each occurrence H or methyl, or R1 is not present;
A is independently on each occurrence selected from the group consisting of C, N S;
a, b, c, d are, independently of each other, an integer selected from 1, 2, 3;
provided that the compound of formula I is not 2,6-dimorpholino-9-benzylpurine;
and the pharmaceutically acceptable salts thereof.